search
Back to results

Treating Adults at Risk for Weight Gain With Interactive Technology (TARGIT)

Primary Purpose

Smoking, Body Weight

Status
Unknown status
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Smoking Cessation
Smoking Cessation plus Weight Loss
Sponsored by
University of Tennessee
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Smoking

Eligibility Criteria

18 Years - 35 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

The selection criteria for the clinical trial are designed to include a wide range of participants such that the study sample will be representative of the broader U.S. population of the Memphis metropolitan area. Those who might be at risk of adverse outcomes from the study interventions will be excluded (see exclusion criteria). All participants will give voluntary consent at the screening visit by signing an informed consent statement which has been approved by the Institutional Review Board (IRB). We will encourage the participation of women and minorities. The study will be open to all persons of any race or gender who are:

  1. *18 to 35 years old
  2. BMI > 22 kg / m2
  3. Self report smoking > 10 cigarettes each day
  4. Have access to a telephone and the internet
  5. Demonstrate ability to access a specific web site
  6. Demonstrate ability to receive and respond to email
  7. Willing to accept random assignment
  8. *Intending to be available for a 24 month intervention
  9. *At risk for weight gain (e.g. plan to quit smoking)

Exclusion Criteria:

Persons will be excluded from the TARGIT study for the following:

  1. *Current participation in a commercial weight loss program (e.g. Weight Watchers, Jenny Craig, etc.), current use of a prescription weight loss medication, planned weight loss surgery within the next 24 months (e.g. gastric bypass, lap band, or liposuction), current or planned enrollment in another diet / physical activity / weight loss study
  2. Currently meet recommendations for physical activity (i.e., 30 minutes or more of moderate physical activity per day on the majority of days each week - 150 minutes or more each week)
  3. *History of cerebral, coronary, or peripheral vascular disease, or serious uncontrolled cardiac arrhythmia, revascularization procedure or uncontrolled congestive heart failure in the past 6 months
  4. Current substance abuse (includes alcohol use in excess of 21 drinks a week)
  5. Uncontrolled hypertension as defined as BP > 140/90 mm Hg
  6. Presence of an unstable psychiatric condition or use of anti-psychotic drugs
  7. History of significant kidney disease or liver disease
  8. History of uncontrolled thyroid disease or pheochromocytoma
  9. Current use of a medication that may interfere with primary study endpoints (e.g. a weight loss medication such as Orlistat, etc) or that may increase the risk of side effects from the study intervention that can not be discontinued
  10. Severe uncontrolled asthma, bronchitis, or emphysema that precludes exercise
  11. Resting heart rate > 100
  12. *Malignancy in the last 5 years (except non-melanoma skin cancer)
  13. Plans to move from the Memphis metropolitan area in the next two years
  14. Current participation in another clinical trial
  15. *Other medical or behavioral factors, that in the judgment of the Principal Investigator, may interfere with study participation or the ability to follow the intervention protocol
  16. *History of diabetes treated with a medication that may cause hypoglycemia such as insulin or an oral hypoglycemic agent
  17. Known allergy or sensitivity to the nicotine patch
  18. *Currently pregnant or gave birth within the last 6 months, currently lactating or breast feeding within the last 3 months, actively planning pregnancy within the next 24 months
  19. *BMI < 18.5 kg / m2 or > 40 kg / m2
  20. *Have a household member on study staff
  21. *Current treatment for an eating disorder
  22. *Unable to provide informed consent
  23. *Regular use of a systemic steroids defined as taking the medication most days of the week
  24. *Use of medications to treat attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD)

Sites / Locations

  • Department of Preventive Medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Tobacco Quitline Group

Tobacco Quitline plus Interactive Technology Group

Arm Description

Outcomes

Primary Outcome Measures

Body Mass Index

Secondary Outcome Measures

Smoking status

Full Information

First Posted
September 9, 2010
Last Updated
June 17, 2013
Sponsor
University of Tennessee
search

1. Study Identification

Unique Protocol Identification Number
NCT01199185
Brief Title
Treating Adults at Risk for Weight Gain With Interactive Technology
Acronym
TARGIT
Official Title
Targeted Approaches to Weight Control for Young Adults
Study Type
Interventional

2. Study Status

Record Verification Date
June 2013
Overall Recruitment Status
Unknown status
Study Start Date
August 2009 (undefined)
Primary Completion Date
October 2014 (Anticipated)
Study Completion Date
October 2014 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Tennessee

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Obesity represents a chronic disease associated with significant cardiovascular disease (CVD) morbidity and mortality. Weight gain in young adults adversely impacts the development of CVD risk factors. Further, there is a clear relationship between weight loss in obese persons and reduction in these CVD risk factors. Unfortunately, young adults are at high risk for weight gain. Although the scientific literature contains a number of reports regarding successful weight loss efficacy studies, young adults are typically underrepresented. Cigarette smoking is the leading preventable cause of morbidity and mortality, but quitting smoking frequently results in significant weight gain. Proactive tobacco quit lines using behavioral smoking cessation interventions combined with nicotine replacement therapy (NRT) have been shown to help persons quit smoking. However, concerns about post-cessation weight gain have been reported as a significant barrier to quitting for many smokers particularly young adults. If an efficacious behavioral weight loss program could be combined with an efficacious behavioral smoking cessation program that prevented or significantly attenuated post-cessation weight gain, then a large public health benefit may result. Such a combined weight loss/ weight gain prevention / smoking cessation program that used targeted intervention strategies to young adults, removed barriers to participation, and utilize interactive technology should be appealing to this age group. To date such a combined program has not been tested in young adult cigarette smokers. Therefore, the objective of this clinical trial is to develop and test a behavioral weight loss / weight gain prevention intervention delivered through interactive technology that can be used in conjunction with an efficacious tobacco quit line. A total of 330 participants will be necessary to adequately address the following specific aims.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Smoking, Body Weight

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
330 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Tobacco Quitline Group
Arm Type
Active Comparator
Arm Title
Tobacco Quitline plus Interactive Technology Group
Arm Type
Experimental
Intervention Type
Behavioral
Intervention Name(s)
Smoking Cessation
Intervention Description
All participants will receive a smoking cessation intervention via the Proactive TARGIT Quit Line. Participants will receive access to the TARGIT Smoking Cessation Handbook which will be a useful tool to guide them through the quitting process and highlight the major points reviewed in all counseling sessions. As part of TARGIT all participants will receive nicotine replacement therapy (NRT).
Intervention Type
Behavioral
Intervention Name(s)
Smoking Cessation plus Weight Loss
Intervention Description
All participants will receive a smoking cessation intervention via the Proactive TARGIT Quit Line. Participants will receive access to the TARGIT Smoking Cessation Handbook which will be a useful tool to guide them through the quitting process and highlight the major points reviewed in all counseling sessions. As part of TARGIT all participants will receive nicotine replacement therapy (NRT). Participants in the Intervention Group will also receive a Behavioral Weight Loss/ Weight Gain Prevention Intervention delivered via interactive technology. The Intervention group will receive 16 weekly webinar sessions beginning 7 weeks after randomization via Cisco WebEx. The webinar sessions will present the behavioral weight loss/ weight gain prevention program. After the 16 weekly sessions, the webinar sessions will then be scheduled monthly for the next 6 months then quarterly thereafter for 12 months.
Primary Outcome Measure Information:
Title
Body Mass Index
Time Frame
24 months after randomization
Secondary Outcome Measure Information:
Title
Smoking status
Time Frame
24 months after randomization

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: The selection criteria for the clinical trial are designed to include a wide range of participants such that the study sample will be representative of the broader U.S. population of the Memphis metropolitan area. Those who might be at risk of adverse outcomes from the study interventions will be excluded (see exclusion criteria). All participants will give voluntary consent at the screening visit by signing an informed consent statement which has been approved by the Institutional Review Board (IRB). We will encourage the participation of women and minorities. The study will be open to all persons of any race or gender who are: *18 to 35 years old BMI > 22 kg / m2 Self report smoking > 10 cigarettes each day Have access to a telephone and the internet Demonstrate ability to access a specific web site Demonstrate ability to receive and respond to email Willing to accept random assignment *Intending to be available for a 24 month intervention *At risk for weight gain (e.g. plan to quit smoking) Exclusion Criteria: Persons will be excluded from the TARGIT study for the following: *Current participation in a commercial weight loss program (e.g. Weight Watchers, Jenny Craig, etc.), current use of a prescription weight loss medication, planned weight loss surgery within the next 24 months (e.g. gastric bypass, lap band, or liposuction), current or planned enrollment in another diet / physical activity / weight loss study Currently meet recommendations for physical activity (i.e., 30 minutes or more of moderate physical activity per day on the majority of days each week - 150 minutes or more each week) *History of cerebral, coronary, or peripheral vascular disease, or serious uncontrolled cardiac arrhythmia, revascularization procedure or uncontrolled congestive heart failure in the past 6 months Current substance abuse (includes alcohol use in excess of 21 drinks a week) Uncontrolled hypertension as defined as BP > 140/90 mm Hg Presence of an unstable psychiatric condition or use of anti-psychotic drugs History of significant kidney disease or liver disease History of uncontrolled thyroid disease or pheochromocytoma Current use of a medication that may interfere with primary study endpoints (e.g. a weight loss medication such as Orlistat, etc) or that may increase the risk of side effects from the study intervention that can not be discontinued Severe uncontrolled asthma, bronchitis, or emphysema that precludes exercise Resting heart rate > 100 *Malignancy in the last 5 years (except non-melanoma skin cancer) Plans to move from the Memphis metropolitan area in the next two years Current participation in another clinical trial *Other medical or behavioral factors, that in the judgment of the Principal Investigator, may interfere with study participation or the ability to follow the intervention protocol *History of diabetes treated with a medication that may cause hypoglycemia such as insulin or an oral hypoglycemic agent Known allergy or sensitivity to the nicotine patch *Currently pregnant or gave birth within the last 6 months, currently lactating or breast feeding within the last 3 months, actively planning pregnancy within the next 24 months *BMI < 18.5 kg / m2 or > 40 kg / m2 *Have a household member on study staff *Current treatment for an eating disorder *Unable to provide informed consent *Regular use of a systemic steroids defined as taking the medication most days of the week *Use of medications to treat attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Karen Johnson, MD, MPH
Organizational Affiliation
University of Tennessee
Official's Role
Principal Investigator
Facility Information:
Facility Name
Department of Preventive Medicine
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38163
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
34611902
Citation
Hartmann-Boyce J, Theodoulou A, Farley A, Hajek P, Lycett D, Jones LL, Kudlek L, Heath L, Hajizadeh A, Schenkels M, Aveyard P. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev. 2021 Oct 6;10(10):CD006219. doi: 10.1002/14651858.CD006219.pub4.
Results Reference
derived
PubMed Identifier
28948720
Citation
Johnson KC, Thomas F, Richey P, Tran QT, Tylavsky F, Miro D, Coday M. The Primary Results of the Treating Adult Smokers at Risk for Weight Gain with Interactive Technology (TARGIT) Study. Obesity (Silver Spring). 2017 Oct;25(10):1691-1698. doi: 10.1002/oby.21968.
Results Reference
derived
Links:
URL
http://www.targitstudy.org
Description
TARGIT study website

Learn more about this trial

Treating Adults at Risk for Weight Gain With Interactive Technology

We'll reach out to this number within 24 hrs